about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

From Aus­tralia, new $173M re­search cen­ter strives to be at the fore­front of pan­dem­ic drug dis­cov­ery

3 years ago
Discovery
Coronavirus

Am­gen posts terse up­date on PhI­II Lumakras win — but just how big?

3 years ago
R&D
Pharma

Two years af­ter PhII set­back, Jounce's lead I/O drug flops again de­spite bio­mark­er ap­proach

3 years ago
R&D

With cash in the bank and an eye on Eu­rope, Neu­ro­crine buys out a Lon­don-based out­fit

3 years ago
Deals

Af­ter clin­i­cal hold quashed its hopes, Yu­man­i­ty field­ed 10 bid­ders be­fore land­ing on two-way deal with J&J, Kine­ta

3 years ago
Deals

Mod­er­na goes on the patent of­fen­sive; Pablo Legor­re­ta dou­bles down; Is a biotech re­cov­ery on the way?; and more

3 years ago
Weekly

Take­da breaks off five-year pact with mi­cro­bio­me part­ner, hand­ing back two pre­clin­i­cal drugs

3 years ago
Deals

No deal for Mer­ck and Seagen yet as talks stall over buy­out price — re­port

3 years ago
Deals

Fac­ing fears of neu­ronal dam­age, No­var­tis slams brakes on Hunt­ing­ton's tri­al

3 years ago
R&D

Na­tal­ie Holles tests the Nas­daq wa­ters with Third Har­mon­ic IPO

3 years ago
Financing

Dragged by PhI­II flop and shelved by Ab­b­Vie, a class of de­pres­sion drugs finds new life at start­up

3 years ago
Startups

Years af­ter Sanofi's Deng­vax­ia fi­as­co, Take­da lands first OK for its own dengue vac­cine

3 years ago
Pharma

Four of­fers and a call from Bourla: How Pfiz­er nar­row­ly beat out ri­val bid­der to swal­low GBT and its sick­le cell ...

3 years ago
Deals

Look­ing to so­lid­i­fy semaglu­tide's reign over GLP-1, No­vo Nordisk posts key PhII win

3 years ago
R&D

Flush with $126M raise, Tes­sa Ther­a­peu­tics woos new CEO from Take­da

3 years ago
People

Roche's big Chi­na play; Mer­ck bets on mR­NA, again; Blue­bird's gene ther­a­py takes off; Bet­ter PhI­II? At a frac­tion of ...

3 years ago
Weekly

Strug­gling pen­ny stock biotech lays off 40% of staffers to stay afloat — for a few more weeks

3 years ago
People

Ex­sci­en­tia ter­mi­nates Bay­er pact half a year ear­ly, col­lect­ing small por­tion of €240M promised

3 years ago
Deals
AI

Squeezed by As­traZeneca/Dai­ichi Sankyo, biotech de­vel­op­ing HER2 ADC switch­es CEO, launch­es pipeline re­view

3 years ago
People
R&D

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

3 years ago
R&D

Buy­ing time to catch up on sales, ADC Ther­a­peu­tics takes on $175M loan

3 years ago
Financing

Atai prunes pipeline, drops out of part­ner­ships as it takes on $175M loan and fo­cus­es on loom­ing da­ta read­outs

3 years ago
Financing
R&D

Car­lyle finds its first big biotech bet af­ter team­ing with Abing­worth

3 years ago
Financing

His­toric drug pric­ing re­forms pass; Pfiz­er ac­quires GBT; The long search for non-opi­oid pain drugs; and more

3 years ago
Weekly
First page Previous page 25262728293031 Next page Last page
A service from the Financial Times